Literature DB >> 11063659

A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix.

T Nakanishi1, H Ishikawa, Y Suzuki, T Inoue, S Nakamura, K Kuzuya.   

Abstract

OBJECTIVES: The influence of the histology of adenocarcinoma on recurrence and survival for patients treated with radical hysterectomy and diagnosed as having pathologic stage Ib cervical cancer was investigated.
METHODS: Five hundred and nine patients (405 squamous cell carcinomas, 104 adenocarcinomas) with pathologic stage Ib cervical cancer treated initially at the Aichi Cancer Center between 1976 and 1995 were studied.
RESULTS: Multivariate analysis identified the prognostic variables as histology of adenocarcinoma, number of lymph nodes involved, and tumor size beyond 4 cm. Five-year overall survival and disease-free survival of patients with adenocarcinoma in the presence of lymph node metastasis were 63.2 and 47.4%, respectively, significantly poorer than for squamous cell carcinoma (83.6 and 80.6%; P < 0.001 and P = 0.002, respectively). These were not different in the absence of lymph node metastasis (adenocarcinoma, 93.9 and 92.7%; squamous cell carcinoma, 97.9% and 96.1%; P = 0.067 and P = 0.250, respectively).
CONCLUSIONS: The independent significant risk factors for the recurrence and survival of pathologic stage Ib cervical cancer were the presence of lymph node metastasis, large tumor size beyond 4 cm, and histology of adenocarcinoma. The prognosis of patients with adenocarcinoma was poorer than of patients with squamous cell carcinoma in the presence of lymph node metastasis, while the prognosis of pathologic stage Ib cervical cancer was equivalent when there was no metastasis. Copyright 2000 Academic Press.

Entities:  

Mesh:

Year:  2000        PMID: 11063659     DOI: 10.1006/gyno.2000.5935

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

Review 1.  Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer.

Authors:  Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

2.  Increased expression of iASPP correlates with poor prognosis in FIGO IA2-IIA cervical adenocarcinoma following a curative resection.

Authors:  Fanming Kong; Xiaofeng Shi; Huzi Li; Pu Li; Jianchun Yu; XiaoJiang Li; Jun Chen; Yiyu Sun; Yingjie Jia
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.

Authors:  Muneaki Shimada; Shoji Nagao; Keiichi Fujiwara; Nobuhiro Takeshima; Ken Takizawa; Tadahiro Shoji; Toru Sugiyama; Satoshi Yamaguchi; Ryuichiro Nishimura; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2016-07-05       Impact factor: 3.402

4.  Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma.

Authors:  Yoshihiko Ino; Taishi Akimoto; Akira Takasawa; Kumi Takasawa; Tomoyuki Aoyama; Asako Ueda; Misaki Ota; Kazufumi Magara; Yohei Tagami; Masaki Murata; Tadashi Hasegawa; Tsuyoshi Saito; Norimasa Sawada; Makoto Osanai
Journal:  Histol Histopathol       Date:  2019-09-04       Impact factor: 2.303

5.  A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.

Authors:  Xiuzhen Xie; Kun Song; Baoxia Cui; Jie Jiang; Xingsheng Yang; Beihua Kong
Journal:  Int J Clin Oncol       Date:  2018-01-03       Impact factor: 3.402

6.  Tumor size and lymph node status determined by imaging are reliable factors for predicting advanced cervical cancer prognosis.

Authors:  Min Sun Kyung; Hong Bae Kim; Jung Yeob Seoung; In Young Choi; Young Soo Joo; Me Yeon Lee; Jung Bae Kang; Young Han Park
Journal:  Oncol Lett       Date:  2015-03-05       Impact factor: 2.967

Review 7.  Adenocarcinoma of the cervix: should we treat it differently?

Authors:  Ned L Williams; Theresa L Werner; Elke A Jarboe; David K Gaffney
Journal:  Curr Oncol Rep       Date:  2015-04       Impact factor: 5.075

8.  Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix.

Authors:  J-Y Park; D-Y Kim; J-H Kim; Y-M Kim; Y-T Kim; J-H Nam
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

9.  Cytoplasmic Maspin Expression Correlates with Poor Prognosis of Patients with Adenocarcinoma of the Uterine Cervix.

Authors:  Kanae Nosaka; Yasushi Horie; Tatsushi Shiomi; Hiroaki Itamochi; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Tomohiko Sakabe; Tasuku Harada; Yoshihisa Umekita
Journal:  Yonago Acta Med       Date:  2015-12-18       Impact factor: 1.641

10.  Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix.

Authors:  T Kasamatsu; T Onda; M Sawada; T Kato; S Ikeda; Y Sasajima; H Tsuda
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.